Nature Research Custom Media’s Post

The rise in prevalence of #leukemia, advancements in R&D, and high effectiveness of #CARTcelltherapy drive market growth. Estimated to reach $35.9 billion by 2032, the CAR T-cell therapy market reflects a #CAGR of 28.5%. Additionally, the surge in demand for generative #AIinhealthcare underscores its potential, with projections reaching $30.4 billion by 2032. #AMR #LifeSciences #HealthcareInnovation #GeneEditing #ArtificialIntelligence #DrugDiscovery #GlobalHealth #CAR-TCellTherapy #3DBioprinting #MassSpectrometry #FlowCytometry #Teleradiology #ImmuneCheckpointInhibitors #GenerativeAI #GastricCancer #TAVR #TumorAblation #HealthcareTrends #MarketGrowth #AdvancedTech #PatientCentric https://lnkd.in/d2gMrEt7

🚨 Major Breakthrough in Lung Disease Treatment! 🚨 A cutting-edge small molecule designed using **generative AI** is making waves in the battle against Idiopathic Pulmonary Fibrosis (IPF). Launched by Insilico Medicine, this innovative drug has shown promising signs of efficacy in early clinical trials【4:0†source】. 🌿 **What This Means for Patients:** Improved treatment options for those battling IPF, a serious lung disease with limited current therapies. 💡 **Behind the Innovation:** The power of AI was harnessed to create a drug candidate specifically designed to combat IPF. This isn't just a leap for lung disease treatment—it's a testament to the game-changing potential of artificial intelligence in medicine. But let’s not stop there. The landscape is competitive, and while this development is significant, it's crucial to keep an eye on other leading players in the field. Continuous advancement and collaboration are key. 👉 **Stay Informed:** Follow us for more updates on breakthroughs and innovations in healthcare and technology. The future of medicine is happening now! #HealthcareInnovation #AIinMedicine #LungDisease #IPFTreatment #GenerativeAI

The approval of Lecanemab (also commonly known as Leqembi) marks a turning point in Alzheimer's treatment, but it's likely just the beginning of a shift toward personalized medicine. Patients may benefit from targeting various stages of amyloid plaque formation or entirely different approaches (E.G., mitochondrial dysfunction repair). With advances in biomarker identification and the rise in innovative therapies targeting specific disease mechanisms, the future holds promise for more effective interventions, emphasizing early detection, personalized treatment strategies, and a shift towards proactive instead of reactive approaches. We're likely going to see increased investment in the industry at large. #Alzheimers #AlzheimersDisease #Leqembi #Lecanemab #PrecisionMedicine

Read the findings from the Sepsis Biomarker Workshop Group workshop, "Enhancing sepsis biomarker development: key considerations from public and private perspectives" https://lnkd.in/g4peKtEp

Article Review https://lnkd.in/gtzSBCVS The article from the Wall Street Journal, titled "Viagra Could Be Good for Your Brain," discusses recent research suggesting that sildenafil (Viagra) might help prevent or even reverse Alzheimer's disease. The study, conducted by the Cleveland Clinic and published in the Journal of Alzheimer’s Disease, used artificial intelligence to identify sildenafil among over 1,600 FDA-approved drugs for its potential in treating Alzheimer's due to its interaction with genes associated with the disease's pathology. Further analysis of insurance claims revealed that individuals taking sildenafil were significantly less likely to develop Alzheimer’s. Laboratory experiments supported these findings, showing sildenafil could increase brain cell growth and decrease toxic tau proteins. The article highlights how AI accelerates drug discovery, repurposing medications for new uses by mapping connections among drugs, genes, and diseases. It notes how drugs like sildenafil, originally developed for hypertension and angina, and others like minoxidil (Rogaine) and hydroxychloroquine, found new uses beyond their initial purposes. The commentary, part of the WSJ's Opinion Spotlight, stresses the potential of AI in bridging the gap between existing medications and treatment for complex diseases like Alzheimer's, suggesting a future where drugs are repurposed with greater efficiency and speed.

CSF biomarkers at time of diagnosis may aid in MS prognosis: Study #waronms #waronmsfoundation #ms #multiplesclerosis @ToNY__411 @waronms @peepswithms

Cardiac Biomarkers

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting https://lnkd.in/dxqcEAYd

Immunochemistry stands as a beacon of innovation, promising breakthroughs in diagnostics, treatment, and disease management. From precision diagnostics to personalized therapeutics, it offers a multifaceted approach to addressing the complex challenges of today’s medical world. Read the exclusive story. #immunochemistry #innovation #breakthroughs #diagnostics #treatment #disease #management #therapeutics #medical #technology #healthcare #research 

The ZEPHYRUS-1 trial led by testing pamrevlumab (CTGF antibody) for #PulmonaryFibrosis published negative results yesterday, also discontinuing ZEPHYRUS-2. JAMA has a good editorial on challenges and ideas for improving predictive validity for #IPF clinical trials: - One is that the IPF label covers a heterogeneous patient population. Genetic risk factors could be used for targeting drugs, though that leaves >70% of patients with no treatment. Broader -omic characterization of patients & preclinical models could reveal which models best match patient subgroups. - Another is the FVC endpoint. Many physicians argue for more nuanced endpoints. But while we're using FVC we should think about how preclin assay map to this, given that it can't be measured in typical rodent models. Larger animals could give more direct comparisons, or when that's not feasible then we should think carefully about how anatomy and pathobiology of models reflect this endpoint. - Preclinical models for are much maligned, with high false positive rates for standard bleo mouse model. The editorial authors suggest focusing on human organoids, although this may be throwing out the baby with the bathwater: IPF is an inflammatory disease with a key role for immune cells, which aren't included in organoid/chip models (yet anyway)... We should also think about in vivo models that address the obvious limitations of the standard bleo mouse model: 1) fibrosis resolves spontaneously, instead of progressing. 2) IPF is strongly age-related, but the mice are usually young. Other species (even rats) have less spontaneous regression of fibrosis, and multiple types of injury might better capture patient exacerbations. And using older animals could capture both known and unknown mechanisms preventing normal regeneration in PF patients. Gordian Biotechnology's Vishwaraj Sontake thinks a lot about predictive validity for complex diseases like IPF. Mapping models to patients is key, and the basis for our 'Patient Avatars' concept. Trials are were biopharma spends the most dollars, so we think it's worth spending more on doing R&D in predictive models. Editorial: https://lnkd.in/gRUFQ5XK